{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:13:32Z","timestamp":1791893612643,"version":"4.3.4"},"reference-count":124,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2020,1,4]]},"DOI":"10.18632\/aging.102646","type":"journal-article","created":{"date-parts":[[2020,1,5]],"date-time":"2020-01-05T01:56:25Z","timestamp":1578189385000},"page":"8-34","source":"Crossref","is-referenced-by-count":136,"title":["Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity"],"prefix":"10.18632","volume":"12","author":[{"given":"Sara","family":"Verdura","sequence":"first","affiliation":[{"name":"Program against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Spain"},{"name":"Girona Biomedical Research Institute (IDIBGI), Girona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Cuy\u00e0s","sequence":"additional","affiliation":[{"name":"Program against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Spain"},{"name":"Girona Biomedical Research Institute (IDIBGI), Girona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Cortada","sequence":"additional","affiliation":[{"name":"Girona Biomedical Research Institute (IDIBGI), Girona, Spain"},{"name":"Cardiovascular Genetics Centre, Department of Medical Sciences, University of Girona, Girona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Brunet","sequence":"additional","affiliation":[{"name":"Medical Oncology, Catalan Institute of Oncology, Girona, Spain"},{"name":"Department of Medical Sciences, Medical School University of Girona, Girona, Spain"},{"name":"Hereditary Cancer Programme, Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain"},{"name":"Hereditary Cancer Programme, Catalan Institute of Oncology (ICO), Girona Biomedical Research Institute (IDIBGI), Girona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugeni","family":"Lopez-Bonet","sequence":"additional","affiliation":[{"name":"Department of Anatomical Pathology, Dr. Josep Trueta Hospital of Girona, Girona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Martin-Castillo","sequence":"additional","affiliation":[{"name":"Unit of Clinical Research, Catalan Institute of Oncology, Girona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Bosch-Barrera","sequence":"additional","affiliation":[{"name":"Girona Biomedical Research Institute (IDIBGI), Girona, Spain"},{"name":"Medical Oncology, Catalan Institute of Oncology, Girona, Spain"},{"name":"Department of Medical Sciences, Medical School University of Girona, Girona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Encinar","sequence":"additional","affiliation":[{"name":"Institute of Research, Development and Innovation in Biotechnology of Elche (IDiBE) and Molecular and Cell Biology Institute (IBMC), Miguel Hern\u00e1ndez University (UMH), Elche, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier A.","family":"Menendez","sequence":"additional","affiliation":[{"name":"Program against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Spain"},{"name":"Girona Biomedical Research Institute (IDIBGI), Girona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2020,1,4]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctrv.2016.03.011","article-title":"The immune system and hormone-receptor positive breast cancer: is it really a dead end?","volume":"4","author":"Guarneri","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"2","doi-asserted-by":"publisher","first-page":"e000255","DOI":"10.1136\/esmoopen-2017-000255","article-title":"Targeting immune checkpoints in breast cancer: an update of early results.","volume":"2","author":"Buisseret","year":"2017","journal-title":"ESMO Open"},{"key":"3","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1158\/1078-0432.CCR-16-2569","article-title":"Immunotherapy for Breast Cancer: What Are We Missing?","volume":"2","author":"Clark","year":"2017","journal-title":"Clin Cancer Res"},{"key":"4","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.6004\/jnccn.2018.7046","article-title":"Immune Checkpoint Inhibitor Therapy in Breast Cancer.","volume":"1","author":"Nanda","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"5","doi-asserted-by":"publisher","first-page":"E628","DOI":"10.3390\/cancers11050628","article-title":"Beyond PD-1\/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy.","volume":"1","author":"Foukakis","year":"2019","journal-title":"Cancers (Basel)"},{"key":"6","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/annonc\/mdu191","article-title":"Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.","volume":"2","author":"Bartlett","year":"2014","journal-title":"Ann Oncol"},{"key":"7","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1093\/annonc\/mdv192","article-title":"PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes.","volume":"2","author":"Caldas","year":"2015","journal-title":"Ann Oncol"},{"key":"8","doi-asserted-by":"publisher","first-page":"e1257452","DOI":"10.1080\/2162402X.2016.1257452","article-title":"Tumor-infiltrating lymphocyte composition, organization and PD-1\/ PD-L1 expression are linked in breast cancer.","volume":"6","author":"Larsimont","year":"2016","journal-title":"Oncoimmunology"},{"key":"9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s12032-017-1071-6","article-title":"Immunotherapy in triple-negative breast cancer.","volume":"3","author":"Alsharedi","year":"2017","journal-title":"Med Oncol"},{"key":"10","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3389\/fimmu.2017.01412","article-title":"Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer.","volume":"8","author":"Craciun","year":"2017","journal-title":"Front Immunol"},{"key":"11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2017.07.002","article-title":"Immunotherapy for triple-negative breast cancer: existing challenges and exciting prospects.","volume":"3","author":"Yang","year":"2017","journal-title":"Drug Resist Updat"},{"key":"12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12967-018-1514-7","article-title":"Immunotherapeutic interventions of Triple Negative Breast Cancer.","volume":"1","author":"Wang","year":"2018","journal-title":"J Transl Med"},{"key":"13","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.celrep.2018.06.066","article-title":"ALIX Regulates Tumor-Mediated Immunosuppression by Controlling EGFR Activity and PD-L1 Presentation.","volume":"2","author":"Wulaningsih","year":"2018","journal-title":"Cell Rep"},{"key":"14","doi-asserted-by":"publisher","first-page":"6823","DOI":"10.2147\/CMAR.S185176","article-title":"The clinical promise of immunotherapy in triple-negative breast cancer.","volume":"1","author":"Zhang","year":"2018","journal-title":"Cancer Manag Res"},{"key":"15","doi-asserted-by":"publisher","first-page":"11671","DOI":"10.1038\/s41598-017-11905-7","article-title":"Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value.","volume":"7","author":"Choi","year":"2017","journal-title":"Sci Rep"},{"key":"16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10549-018-4745-7","article-title":"The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.","volume":"17","author":"Khoury","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41523-018-0072-8","article-title":"Is there a role for immunotherapy in HER2-positive breast cancer?","volume":"4","author":"Cortes","year":"2018","journal-title":"NPJ Breast Cancer"},{"key":"18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.canlet.2018.10.042","article-title":"Immunological therapy: A novel thriving area for triple-negative breast cancer treatment.","volume":"44","author":"Fang","year":"2019","journal-title":"Cancer Lett"},{"key":"19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/BCTT.S175360","article-title":"Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches.","volume":"1","author":"Yaghan","year":"2019","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40425-019-0548-6","article-title":"Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer.","volume":"7","author":"Prat","year":"2019","journal-title":"J Immunother Cancer"},{"key":"21","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy.","volume":"1","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"22","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment.","volume":"8","author":"Chen","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"23","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrd3877","article-title":"Advances in targeting cell surface signalling molecules for immune modulation.","volume":"1","author":"Chen","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"24","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.","volume":"3","author":"Buisseret","year":"2016","journal-title":"J Clin Oncol"},{"key":"25","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.","volume":"37","author":"Chui","year":"2018","journal-title":"N Engl J Med"},{"key":"26","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/annonc\/mdy518","article-title":"Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.","volume":"3","author":"Ryvo","year":"2019","journal-title":"Ann Oncol"},{"key":"27","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.","volume":"3","author":"Toppmeyer","year":"2019","journal-title":"Ann Oncol"},{"key":"28","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s10549-017-4537-5","article-title":"Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.","volume":"16","author":"Edenfield","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"29","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1158\/1538-7445.am2017-2986","article-title":"Abstract 2986: atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses.","volume":"7","author":"Liu","year":"2017","journal-title":"Cancer Res"},{"key":"30","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40425-016-0109-1","article-title":"Metabolic communication in tumors: a new layer of immunoregulation for immune evasion.","volume":"4","author":"Liu","year":"2016","journal-title":"J Immunother Cancer"},{"key":"31","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/imm.12777","article-title":"Metabolic reprogramming in the tumour microenvironment: a hallmark shared by cancer cells and T lymphocytes.","volume":"15","author":"Bridle","year":"2017","journal-title":"Immunology"},{"key":"32","doi-asserted-by":"publisher","first-page":"400","DOI":"10.4049\/jimmunol.1701041","article-title":"Metabolic Barriers to T Cell Function in Tumors.","volume":"20","author":"Rathmell","year":"2018","journal-title":"J Immunol"},{"key":"33","doi-asserted-by":"publisher","first-page":"dmm034272","DOI":"10.1242\/dmm.034272","article-title":"Immunometabolism in cancer at a glance.","volume":"1","author":"Siska","year":"2018","journal-title":"Dis Model Mech"},{"key":"34","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41571-019-0203-7","article-title":"Navigating metabolic pathways to enhance antitumour immunity and immunotherapy.","volume":"1","author":"Ho","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"35","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3389\/fimmu.2017.00248","article-title":"Metabolic Hallmarks of Tumor and Immune Cells in the Tumor Microenvironment.","volume":"8","author":"Kreutz","year":"2017","journal-title":"Front Immunol"},{"key":"36","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.pharmthera.2018.11.004","article-title":"Altered cancer metabolism in mechanisms of immunotherapy resistance.","volume":"19","author":"Cortez","year":"2019","journal-title":"Pharmacol Ther"},{"key":"37","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3389\/fimmu.2018.00353","article-title":"Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy.","volume":"9","author":"Benammar Elgaaied","year":"2018","journal-title":"Front Immunol"},{"key":"38","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/bs.acr.2019.03.004","article-title":"Immunometabolism: A new target for improving cancer immunotherapy.","volume":"14","author":"Wang","year":"2019","journal-title":"Adv Cancer Res"},{"key":"39","doi-asserted-by":"publisher","first-page":"e1633235","DOI":"10.1080\/2162402X.2019.1633235","article-title":"Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy.","volume":"8","author":"Menendez","year":"2019","journal-title":"Oncoimmunology"},{"key":"40","doi-asserted-by":"publisher","first-page":"E563","DOI":"10.3390\/ijms19020563","article-title":"Regulation of Programmed Death Ligand 1 (PD-L1) Expression in Breast Cancer Cell Lines In Vitro and in Immunodeficient and Humanized Tumor Mice.","volume":"1","author":"Brockhoff","year":"2018","journal-title":"Int J Mol Sci"},{"key":"41","doi-asserted-by":"publisher","first-page":"12632","DOI":"10.1038\/ncomms12632","article-title":"Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity.","volume":"7","author":"Hsu","year":"2016","journal-title":"Nat Commun"},{"key":"42","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1038\/s41598-017-03635-7","article-title":"Induction of sirtuin-1 signaling by resveratrol induces human chondrosarcoma cell apoptosis and exhibits antitumor activity.","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"43","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3892\/or.2015.4332","article-title":"Resveratrol induces human keratinocyte damage via the activation of class III histone deacetylase, Sirt1.","volume":"3","author":"Lee","year":"2016","journal-title":"Oncol Rep"},{"key":"44","doi-asserted-by":"publisher","first-page":"8037","DOI":"10.3892\/mmr.2017.7612","article-title":"Resveratrol inhibits proliferation and migration through SIRT1 mediated post-translational modification of PI3K\/AKT signaling in hepatocellular carcinoma cells.","volume":"1","author":"Li","year":"2017","journal-title":"Mol Med Rep"},{"key":"45","doi-asserted-by":"publisher","first-page":"e73097","DOI":"10.1371\/journal.pone.0073097","article-title":"Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells.","volume":"8","author":"Bitzer","year":"2013","journal-title":"PLoS One"},{"key":"46","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.3390\/nu6104273","article-title":"The role of dietary histone deacetylases (HDACs) inhibitors in health and disease.","volume":"6","author":"Barnett","year":"2014","journal-title":"Nutrients"},{"key":"47","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1002\/ijc.24928","article-title":"Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1\/NuRD complex.","volume":"12","author":"Levenson","year":"2010","journal-title":"Int J Cancer"},{"key":"48","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1128\/MCB.26.1.28-38.2006","article-title":"Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage.","volume":"2","author":"Huber","year":"2006","journal-title":"Mol Cell Biol"},{"key":"49","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.canlet.2015.11.032","article-title":"Resveratrol triggers ER stress-mediated apoptosis by disrupting N-linked glycosylation of proteins in ovarian cancer cells.","volume":"37","author":"Song","year":"2016","journal-title":"Cancer Lett"},{"key":"50","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ccell.2018.01.009","article-title":"Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1.","volume":"3","author":"Chou","year":"2018","journal-title":"Cancer Cell"},{"key":"51","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jnutbio.2017.05.008","article-title":"\u03b1-Glucosidase inhibitory effect of resveratrol and piceatannol.","volume":"4","author":"Mathews","year":"2017","journal-title":"J Nutr Biochem"},{"key":"52","first-page":"1243","article-title":"Antioxidant activity and inhibition of alpha-glucosidase by trans-resveratrol, piceid, and a novel trans-stilbene from the roots of Israeli Rumex bucephalophorus L.","volume":"5","author":"Sivan","year":"2006","journal-title":"J Agric Food Chem"},{"key":"53","doi-asserted-by":"publisher","first-page":"E74","DOI":"10.3390\/antiox8030074","article-title":"Resveratrol Anti-Obesity Effects: Rapid Inhibition of Adipocyte Glucose Utilization.","volume":"8","author":"L\u00f3pez","year":"2019","journal-title":"Antioxidants"},{"key":"54","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.foodchem.2016.08.034","article-title":"Ability of resveratrol to inhibit advanced glycation end product formation and carbohydrate-hydrolyzing enzyme activity, and to conjugate methylglyoxal.","volume":"21","author":"Sheng","year":"2017","journal-title":"Food Chem"},{"key":"55","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.devcel.2005.09.017","article-title":"A role for SIR-2.1 regulation of ER stress response genes in determining C. elegans life span.","volume":"9","author":"Guarente","year":"2005","journal-title":"Dev Cell"},{"key":"56","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1474-9726.2009.00471.x","article-title":"Reduced expression of alpha-1,2-mannosidase I extends lifespan in Drosophila melanogaster and Caenorhabditis elegans.","volume":"8","author":"Wang","year":"2009","journal-title":"Aging Cell"},{"key":"57","doi-asserted-by":"publisher","first-page":"13563","DOI":"10.1074\/jbc.M113.460436","article-title":"Specificity of Processing \u03b1-glucosidase I is guided by the substrate conformation: crystallographic and in silico studies.","volume":"28","author":"Rose","year":"2013","journal-title":"J Biol Chem"},{"key":"58","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/s41467-017-01263-3","article-title":"Structure of human lysosomal acid \u03b1-glucosidase-a guide for the treatment of Pompe disease.","volume":"8","author":"Sulzenbacher","year":"2017","journal-title":"Nat Commun"},{"key":"59","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/S0140-6736(02)08905-5","article-title":"Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.","volume":"35","author":"Laakso","year":"2002","journal-title":"Lancet"},{"key":"60","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/acel.12170","article-title":"Acarbose, 17-\u03b1-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males.","volume":"1","author":"Simpkins","year":"2014","journal-title":"Aging Cell"},{"key":"61","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3233\/NHA-160007","article-title":"Targeting glucose metabolism for healthy aging.","volume":"4","author":"Smith","year":"2016","journal-title":"Nutr Healthy Aging"},{"key":"62","doi-asserted-by":"publisher","first-page":"E1821","DOI":"10.3390\/nu10121821","article-title":"Calorie Restriction Mimetics: Upstream-Type Compounds for Modulating Glucose Metabolism.","volume":"1","author":"Sato","year":"2018","journal-title":"Nutrients"},{"key":"63","doi-asserted-by":"publisher","first-page":"e12898","DOI":"10.1111\/acel.12898","article-title":"Acarbose improves health and lifespan in aging HET3 mice.","volume":"1","author":"Macchiarini","year":"2019","journal-title":"Aging Cell"},{"key":"64","doi-asserted-by":"publisher","first-page":"E7890","DOI":"10.1073\/pnas.1611213113","article-title":"Substrate recognition and catalysis by GH47 \u03b1-mannosidases involved in Asn-linked glycan maturation in the mammalian secretory pathway.","volume":"11","author":"Moremen","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"65","first-page":"15599","article-title":"Kifunensine, a potent inhibitor of the glycoprotein processing mannosidase I.","volume":"26","author":"Kaushal","year":"1990","journal-title":"J Biol Chem"},{"key":"66","doi-asserted-by":"publisher","first-page":"13812","DOI":"10.1021\/bi034742r","article-title":"Comparison of kifunensine and 1-deoxymannojirimycin binding to class I and II alpha-mannosidases demonstrates different saccharide distortions in inverting and retaining catalytic mechanisms.","volume":"4","author":"Rose","year":"2003","journal-title":"Biochemistry"},{"key":"67","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.molcel.2018.07.030","article-title":"Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1.","volume":"7","author":"Kuo","year":"2018","journal-title":"Mol Cell"},{"key":"68","doi-asserted-by":"publisher","first-page":"e88557","DOI":"10.1371\/journal.pone.0088557","article-title":"PD-L1 expression is increased in a subset of basal type breast cancer cells.","volume":"9","author":"Antonia","year":"2014","journal-title":"PLoS One"},{"key":"69","doi-asserted-by":"publisher","first-page":"479","DOI":"10.4049\/jimmunol.1201264","article-title":"Enzymatic discovery of a HER-2\/neu epitope that generates cross-reactive T cells.","volume":"19","author":"Knutson","year":"2013","journal-title":"J Immunol"},{"key":"70","doi-asserted-by":"publisher","first-page":"e3683","DOI":"10.3791\/3683","article-title":"Determining optimal cytotoxic activity of human Her2neu specific CD8 T cells by comparing the Cr51 release assay to the xCELLigence system.","volume":"6","author":"Knutson","year":"2012","journal-title":"J Vis Exp"},{"key":"71","doi-asserted-by":"publisher","first-page":"30323","DOI":"10.18632\/oncotarget.8730","article-title":"Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).","volume":"7","author":"Holak","year":"2016","journal-title":"Oncotarget"},{"key":"72","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1021\/acs.jmedchem.7b00293","article-title":"Small-Molecule Inhibitors of the Programmed Cell Death-1\/Programmed Death-Ligand 1 (PD-1\/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1.","volume":"6","author":"Holak","year":"2017","journal-title":"J Med Chem"},{"key":"73","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.str.2017.06.011","article-title":"Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1\/PD-L2.","volume":"2","author":"Holak","year":"2017","journal-title":"Structure"},{"key":"74","doi-asserted-by":"publisher","first-page":"4840","DOI":"10.1002\/anie.201710407","article-title":"Immune Checkpoint PD-1\/PD-L1: Is There Life Beyond Antibodies?","volume":"5","author":"D\u00f6mling","year":"2018","journal-title":"Angew Chem Int Ed Engl"},{"key":"75","doi-asserted-by":"publisher","first-page":"16727","DOI":"10.1038\/s41598-019-53216-z","article-title":"Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method.","volume":"9","author":"No","year":"2019","journal-title":"Sci Rep"},{"key":"76","doi-asserted-by":"publisher","first-page":"E2071","DOI":"10.3390\/molecules24112071","article-title":"Development of the Inhibitors that Target the PD-1\/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles.","volume":"2","author":"Holak","year":"2019","journal-title":"Molecules"},{"key":"77","doi-asserted-by":"publisher","first-page":"764","DOI":"10.3389\/fchem.2019.00764","article-title":"Computational Insight Into the Small Molecule Intervening PD-L1 Dimerization and the Potential Structure-Activity Relationship.","volume":"7","author":"Yao","year":"2019","journal-title":"Front Chem"},{"key":"78","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.cmet.2012.04.003","article-title":"SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function.","volume":"1","author":"Davis","year":"2012","journal-title":"Cell Metab"},{"key":"79","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2337\/db09-0482","article-title":"AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol.","volume":"5","author":"Chung","year":"2010","journal-title":"Diabetes"},{"key":"80","doi-asserted-by":"publisher","first-page":"E751","DOI":"10.3390\/nu9070751","article-title":"Resveratrol-Induced AMP-Activated Protein Kinase Activation Is Cell-Type Dependent: Lessons from Basic Research for Clinical Application.","volume":"9","author":"Ido","year":"2017","journal-title":"Nutrients"},{"key":"81","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3389\/fonc.2015.00138","article-title":"Biosynthetic Machinery Involved in Aberrant Glycosylation: Promising Targets for Developing of Drugs Against Cancer.","volume":"5","author":"Todeschini","year":"2015","journal-title":"Front Oncol"},{"key":"82","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1093\/glycob\/cwz029","article-title":"Characterizing the selectivity of ER \u03b1-glucosidase inhibitors.","volume":"2","author":"High","year":"2019","journal-title":"Glycobiology"},{"key":"83","doi-asserted-by":"publisher","first-page":"6349","DOI":"10.1158\/0008-5472.CAN-18-1892","article-title":"Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy.","volume":"7","author":"Hung","year":"2018","journal-title":"Cancer Res"},{"key":"84","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms Controlling PD-L1 Expression in Cancer.","volume":"7","author":"Hung","year":"2019","journal-title":"Mol Cell"},{"key":"85","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ccell.2019.06.008","article-title":"Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1\/PD-L1 Therapeutic Efficacy.","volume":"3","author":"Chiang","year":"2019","journal-title":"Cancer Cell"},{"key":"86","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1749-6632.2010.05842.x","article-title":"Bioavailability of resveratrol.","volume":"121","author":"Walle","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"87","doi-asserted-by":"publisher","first-page":"e19881","DOI":"10.1371\/journal.pone.0019881","article-title":"What is new for an old molecule? Systematic review and recommendations on the use of resveratrol.","volume":"6","author":"Nalini","year":"2011","journal-title":"PLoS One"},{"key":"88","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.semcancer.2017.11.003","article-title":"Breast cancer genomics and immuno-oncological markers to guide immune therapies.","volume":"5","author":"Debets","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.ircmb.2016.09.008","article-title":"Breast Cancer Immunology and Immunotherapy: Current Status and Future Perspectives.","volume":"33","author":"S\u00e1nchez-Margalet","year":"2017","journal-title":"Int Rev Cell Mol Biol"},{"key":"90","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s12094-018-1907-3","article-title":"New horizons in breast cancer: the promise of immunotherapy.","volume":"2","author":"S\u00e1nchez-Margalet","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"91","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3892\/ijo.2018.4512","article-title":"Upregulation of PD-L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3\/p300-mediated NF-\u03baB signaling.","volume":"5","author":"Wu","year":"2018","journal-title":"Int J Oncol"},{"key":"92","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1530\/ERC-17-0376","article-title":"Thyroxine inhibits resveratrol-caused apoptosis by PD-L1 in ovarian cancer cells.","volume":"2","author":"Lin","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"93","doi-asserted-by":"publisher","first-page":"110693","DOI":"10.1016\/j.fct.2019.110693","article-title":"Thyroid hormone-induced expression of inflammatory cytokines interfere with resveratrol-induced anti-proliferation of oral cancer cells.","volume":"13","author":"Liu","year":"2019","journal-title":"Food Chem Toxicol"},{"key":"94","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13027-019-0247-4","article-title":"Resveratrol induces immunogenic cell death of human and murine ovarian carcinoma cells.","volume":"1","author":"Liu","year":"2019","journal-title":"Infect Agent Cancer"},{"key":"95","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","article-title":"The hallmarks of aging.","volume":"15","author":"Kroemer","year":"2013","journal-title":"Cell"},{"key":"96","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1182\/blood-2015-05-638338","article-title":"PD-L1 blockade: rejuvenating T cells in CLL.","volume":"12","author":"van der Windt","year":"2015","journal-title":"Blood"},{"key":"97","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.7150\/jca.30723","article-title":"Aging, Cancer and Immunity.","volume":"1","author":"Zhang","year":"2019","journal-title":"J Cancer"},{"key":"98","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00281-018-0697-6","article-title":"Does patient age influence anti-cancer immunity?","volume":"4","author":"Pawelec","year":"2019","journal-title":"Semin Immunopathol"},{"key":"99","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3389\/fphar.2019.00200","article-title":"The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma.","volume":"1","author":"Wainwright","year":"2019","journal-title":"Front Pharmacol"},{"key":"100","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1002\/ijc.31875","article-title":"Comprehensive transcriptome profiling in elderly cancer patients reveals aging-altered immune cells and immune checkpoints.","volume":"14","author":"Fan","year":"2019","journal-title":"Int J Cancer"},{"key":"101","article-title":"Understanding the effects of a calorie restriction mimetics on renal cancer progression and CD8 T cell immunity.","volume":"19","author":"Norian","year":"2017","journal-title":"J Immunol"},{"key":"102","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.sabcs18-509","volume-title":"In: Proceedings of the American Association for Cancer Research Annual Meeting 2019;","volume":"79","author":"Norian","year":"2019"},{"key":"103","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.cmet.2011.10.002","article-title":"Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans.","volume":"1","author":"Kunz","year":"2011","journal-title":"Cell Metab"},{"key":"104","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.nutres.2012.06.003","article-title":"Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus.","volume":"3","author":"Nanjan","year":"2012","journal-title":"Nutr Res"},{"key":"105","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/mnfr.201400173","article-title":"Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus\u2014systematic review and meta-analysis.","volume":"5","author":"Smoliga","year":"2015","journal-title":"Mol Nutr Food Res"},{"key":"106","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1093\/gerona\/glw149","article-title":"Strategies and Challenges in Clinical Trials Targeting Human Aging.","volume":"7","author":"Barzilai","year":"2016","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"107","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1021\/jf980788t","article-title":"Inhibitory effect of alpha-glucosidase inhibitors varies according to its origin.","volume":"4","author":"Osajima","year":"1999","journal-title":"J Agric Food Chem"},{"key":"108","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/0047-6374(83)90048-9","article-title":"Quantitative measures of aging in the nematode Caenorhabditis elegans: II. Lysosomal hydrolases as markers of senescence.","volume":"2","author":"Russell","year":"1983","journal-title":"Mech Ageing Dev"},{"key":"109","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.3389\/fphar.2018.01255","article-title":"Is Resveratrol a Cancer Immunomodulatory Molecule?","volume":"9","author":"An","year":"2018","journal-title":"Front Pharmacol"},{"key":"110","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3389\/fphar.2018.00536","article-title":"Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion.","volume":"9","author":"Xu","year":"2018","journal-title":"Front Pharmacol"},{"key":"111","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.neo.2017.02.006","article-title":"Identifying Regulatory Posttranslational Modifications of PD-L1: A Focus on Monoubiquitinaton.","volume":"1","author":"Middleton","year":"2017","journal-title":"Neoplasia"},{"key":"112","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41551-019-0375-6","article-title":"Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours.","volume":"3","author":"Xue","year":"2019","journal-title":"Nat Biomed Eng"},{"key":"113","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41589-018-0161-x","article-title":"HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity.","volume":"1","author":"Xu","year":"2019","journal-title":"Nat Chem Biol"},{"key":"114","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/s41467-018-04313-6","article-title":"STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion.","volume":"9","author":"Lim","year":"2018","journal-title":"Nat Commun"},{"key":"115","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1093\/bioinformatics\/btu426","article-title":"YASARA View - molecular graphics for all devices - from smartphones to workstations.","volume":"3","author":"Vriend","year":"2014","journal-title":"Bioinformatics"},{"key":"116","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/prot.20251","article-title":"Making optimal use of empirical energy functions: force-field parameterization in crystal space.","volume":"5","author":"Vriend","year":"2004","journal-title":"Proteins"},{"key":"117","doi-asserted-by":"publisher","DOI":"10.1002\/0471250953.bi0814s24","article-title":"Using AutoDock for ligand-receptor docking.","author":"Olson","year":"2008","journal-title":"Curr Protoc Bioinformatics"},{"key":"118","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility.","volume":"3","author":"Olson","year":"2009","journal-title":"J Comput Chem"},{"key":"119","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.2174\/1568026614666140929124445","article-title":"Structure-based virtual screening for drug discovery: principles, applications and recent advances.","volume":"1","author":"Cournia","year":"2014","journal-title":"Curr Top Med Chem"},{"key":"120","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jmgm.2006.02.009","article-title":"Fast empirical pKa prediction by Ewald summation.","volume":"2","author":"Vriend","year":"2006","journal-title":"J Mol Graph Model"},{"key":"121","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.fct.2019.03.049","article-title":"The extra virgin olive oil phenolic oleacein is a dual substrate-inhibitor of catechol-O-methyltransferase.","volume":"12","author":"Menendez","year":"2019","journal-title":"Food Chem Toxicol"},{"key":"122","doi-asserted-by":"publisher","first-page":"110645","DOI":"10.1016\/j.fct.2019.110645","article-title":"Revisiting silibinin as a novobiocin-like Hsp90 C-terminal inhibitor: computational modeling and experimental validation.","volume":"13","author":"Menendez","year":"2019","journal-title":"Food Chem Toxicol"},{"key":"123","doi-asserted-by":"publisher","first-page":"E1656","DOI":"10.3390\/nu11071656","article-title":"Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1\/KDM1A.","volume":"1","author":"Segura-Carretero","year":"2019","journal-title":"Nutrients"},{"key":"124","doi-asserted-by":"publisher","first-page":"W443","DOI":"10.1093\/nar\/gkv315","article-title":"PLIP: fully automated protein-ligand interaction profiler.","volume":"4","author":"Schroeder","year":"2015","journal-title":"Nucleic Acids Res"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.102646","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T19:45:09Z","timestamp":1599075909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.102646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,4]]},"references-count":124,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,15]]}},"alternative-id":["102646","31901900"],"URL":"https:\/\/doi.org\/10.18632\/aging.102646","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,4]]}}}